{{Drugbox
| IUPAC_name = (±)-10,11-dihydro-''N'',5-dimethyl-5''H''-dibenz[b,f]azepin-10-amine
| image = Metapramine skeletal.svg
| width = 200px

<!--Clinical data-->
| tradename = Prodastene, Timaxel
| pregnancy_category = 
| legal_status = Rx-only
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| metabolism = 
| elimination_half-life = 7–8 hours
| excretion = 

<!--Identifiers-->
| CAS_number = 21730-16-5
| ATC_prefix = none
| ATC_suffix = 
| PubChem = 65700
| ChemSpiderID = 59127
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 303954M7YF

<!--Chemical data-->
| C=16 | H=18 | N=2 
| molecular_weight = 238.33 g/mol
| SMILES = CNC1CC2=C(C=CC=C2)N(C)C3=CC=CC=C31
| chirality = [[Racemic mixture]]
}}

'''Metapramine''' (brand names '''Prodastene''', '''Timaxel''') is a [[tricyclic antidepressant]] (TCA) developed by Rhone Poulenc<ref>US Patent 3622565 - DIBENZAZEPINE DERIVATIVES AND THEIR PREPARATION</ref> that was introduced for the treatment of [[Major depressive disorder|depression]] in [[France]] in 1984.<ref name="isbn0-412-54090-8">{{cite book | title = Dictionary of organic compounds | publisher = Chapman & Hall | location = London | year = 1996 | page = 13 | isbn = 0-412-54090-8 | oclc = | doi = | url = https://books.google.com/books?id=kfhQgpqxiVgC&lpg=PA1&dq=metapramine&as_brr=3&pg=PA13#v=onepage&q=metapramine&f=false}}</ref><ref name="isbn3-527-31058-4">{{cite book |author1=José Miguel Vela |author2=Helmut Buschmann |author3=Jörg Holenz |author4=Antonio Párraga |author5=Antoni Torrens | title = Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application | publisher = Wiley-VCH | location = Weinheim | year = 2007 | page = 248 | isbn = 3-527-31058-4 | oclc = | doi = | url = https://books.google.com/books?id=yXD4QA-Y_Z0C&lpg=PA248&dq=metapramine&as_brr=3&pg=PA248#v=onepage&q=&f=false}}</ref> In addition to its efficacy against [[affective disorder]]s, it also has [[analgesic]] properties,<ref name="pmid2827090">{{cite journal |vauthors=Michael-Titus A, Costentin J | title = Analgesic effects of metapramine and evidence against the involvement of endogenous enkephalins in the analgesia induced by tricyclic antidepressants | journal = Pain | volume = 31 | issue = 3 | pages = 391–400 |date=December 1987 | pmid = 2827090 | doi = 10.1016/0304-3959(87)90167-9| url = }}</ref><ref name="pmid1731171">{{cite journal |vauthors=Fialip J, Marty H, Aumaitre O, etal | title = Antinociceptive activity of metapramine in mice. Relationship with its pharmacokinetic properties | journal = Life Sciences | volume = 50 | issue = 3 | pages = 161–8 | year = 1992 | pmid = 1731171 | doi = 10.1016/0024-3205(92)90268-T| url = }}</ref> and may be useful in the treatment of [[pain]].

Metapramine has [[desipramine]]-like effects, acting as a [[norepinephrine reuptake inhibitor]] without affecting the [[reuptake]] of [[serotonin]] or [[dopamine]].<ref name="pmid3017518">{{cite journal |vauthors=Dagonneau H, Fonlupt P, Pacheco H | title = [Effects, in rats, of metapramine and carpipramine on the uptake of catecholamines and serotonin; relationship with 3H-imipramine binding] | language = French | journal = Comptes rendus des séances de la Société de biologie et de ses filiales | volume = 180 | issue = 1 | pages = 43–8 | year = 1986 | pmid = 3017518 | doi = | url = }}</ref><ref name="pmid2106711">{{cite journal |vauthors=Warter JM, Tranchant C, Marescaux C, Depaulis A, Lannes B, Vergnes M | title = Immediate effects of 14 non MAOI antidepressants in rats with spontaneous petit mal-like seizures | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 14 | issue = 2 | pages = 261–70 | year = 1990 | pmid = 2106711 | doi = 10.1016/0278-5846(90)90106-q| url = }}</ref><ref name="pmid1033059">{{cite journal |vauthors=Bonierbale M, Dufour H, Scotto JC, Sutter JM | title = [Metapramine: antidepressant and psycho-stimulant] | language = French | journal = L'Encéphale | volume = 2 | issue = 3 | pages = 219–23 | year = 1976 | pmid = 1033059 | doi = | url = }}</ref> It has also been shown to act as a low-[[affinity (pharmacology)|affinity]] [[NMDA receptor]] [[NMDA receptor antagonist|antagonist]].<ref name="pmid9076749">{{cite journal |vauthors=Boireau A, Bordier F, Durand G, Doble A | title = The antidepressant metapramine is a low-affinity antagonist at N-methyl-D-aspartic acid receptors | journal = Neuropharmacology | volume = 35 | issue = 12 | pages = 1703–7 | year = 1996 | pmid = 9076749 | doi = 10.1016/S0028-3908(96)00122-0| url = http://linkinghub.elsevier.com/retrieve/pii/S0028390896001220}}</ref> Metapramine's direct effects on [[serotonin receptor|serotonin]], [[histamine receptor|histamine]], and [[muscarinic acetylcholine receptor]]s have not been assayed, but uniquely among most TCAs, it has anecdotally been reported to lack [[anticholinergic]] effects.<ref name="pmid1033059"/><ref name="pmid2634929">{{cite journal |vauthors=Dufour P, Billa JP, Fabre J, Roquebert J | title = [Evaluation of the central anticholinergic activity of antidepressants. Comparison of two experimental methods] | language = French | journal = Annales Pharmaceutiques Françaises | volume = 47 | issue = 3 | pages = 135–41 | year = 1989 | pmid = 2634929 | doi = | url = }}</ref>

==References==
{{Reflist|30em}}

{{Antidepressants}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Glutamate receptor modulators}}
{{Histamine receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Dibenzazepines]]
[[Category:Tricyclic antidepressants]]


{{nervous-system-drug-stub}}